Gemcitabine (Gem), a primary treatment for advanced and metastatic bladder cancer, can lead to malignant progression and drug resistance, though the underlying mechanisms are not fully understood. Post-translational modifications (PTMs) are key to understandin... ...

请注册登录后继续浏览